Investment Thesis
Decoy Therapeutics is a pre-revenue pharmaceutical company with zero sales, significant operating losses (-$2.3M), and a cash burn rate of -$3.5M annually, providing only ~2.2 years of runway at current burn rates. The company exhibits no revenue generation, worsening net income trends (-124.5% YoY), and lack of insider confidence with zero Form 4 filings in 90 days, indicating fundamental business model failure or extreme development stage risk without offsetting pipeline strength demonstrated in available metrics.
Strengths
- Strong cash position of $7.8M representing 93% of total assets
- Negligible debt burden with 0.00x debt-to-equity ratio eliminating refinancing risk
- Adequate liquidity with 1.84x current ratio and 1.81x quick ratio for near-term obligations
Risks
- Catastrophic cash burn of -$3.5M annually with only ~2.2 years of cash runway before insolvency
- Complete absence of revenue generation with zero sales despite prior-year existence, indicating pipeline failure or pre-clinical stage
- Deteriorating profitability trend with net income declining 124.5% YoY and worsening operating losses
- Zero insider purchasing activity over 90 days suggests management has no confidence in turnaround
Key Metrics to Watch
- Monthly cash burn rate and projected runway extension timeline
- Revenue generation or clinical trial milestone announcements
- Capital raise announcements or dilutive financing events
Financial Metrics
Revenue
0.0
Net Income
-2.2M
EPS (Diluted)
$-4.18
Free Cash Flow
-3.5M
Total Assets
8.4M
Cash
7.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-57.4%
ROA
-26.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.84x
Quick Ratio
1.81x
Debt/Equity
0.00x
Debt/Assets
54.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:05:32.128748 |
Data as of: 2026-03-31 |
Powered by Claude AI